Update on emerging biomarkers in lung cancer | Zendy

Eric Bernicker | Zendy; Timothy Craig Allen | Zendy; Phillip T. Cagle | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Update on emerging biomarkers in lung cancer

Author(s) -

Eric Bernicker,

Timothy Craig Allen,

Phillip T. Cagle

Publication year - 2019

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2019.01.46

Subject(s) - medicine , lung cancer , biomarker , disease , biomarker discovery , cancer , targeted therapy , bioinformatics , molecular biomarkers , precision medicine , intensive care medicine , oncology , pathology , proteomics , gene , biology , biochemistry

There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research